About Dfe Pharma India Private Limited
Data last updated:
Dfe Pharma India Private Limited is a foreign private limited company based in Cuddalore, Tamil Nadu, India, a subsidiary of Dfe Pharma B.V, Netherlands. It operates in the business support services segment of the business services sector. It was incorporated on 15 May 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U24299TN2019FTC129309. Its GSTIN is 33AAHCD2694R1Z0 (Tamil Nadu). The company holds 4 GST registrations, all of them active.
The company has an authorised share capital of ₹61.12 Cr and a paid-up capital of ₹61.12 Cr. It is led by directors including Jaya Prabbu Subbaraj and Aditya Chitharanjan.
Its last annual general meeting (AGM) was held on 18 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at B – 4 Sipcot Industrial Complex Kudikadu, Cuddalore, Tamil Nadu, India – 607005.
As per the financials filed for FY 2025, the company reported a revenue of ₹571.98 Cr, a growth of 26% compared to the previous year. For the same year it recorded a net profit of ₹13.91 Cr (net margin 2.4%) and EBITDA of ₹30.29 Cr (EBITDA margin 5.3%). Revenue has grown at a compounded annual rate (CAGR) of 28% over three years and 29% over five years.
The company has about 134 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: DFE Pharma. Court records list 6 cases involving the company, including 6 filed by the company. The company has 2 deals on record (2 secondary share transfers); the latest was in March 2022. Its 5 peer companies in the Business Services industry (Business Auxiliary Services, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 4 smaller; the largest is H.B. Fuller India Adhesives Private Limited with revenue of ₹575.65 Cr. The company has 12 MSME Form 1 returns on record between 2020 and 2024, listing 1,071 overdue payments to 53 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dfepharma.com.
Company details
Contact details
Dfe Pharma India Private Limited's registered office is in Cuddalore, Tamil Nadu. Its website is dfepharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressB – 4 Sipcot Industrial Complex Kudikadu, Cuddalore, Tamil Nadu, India – 607005
- IndustryBusiness Services, Business Support Services
To see the full contact details of Dfe Pharma India Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Dfe Pharma India operates one associated brand: DFE Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Developer and manufacturer of excipients for oral solid dosage forms and dry powder inhalations | dfepharma.com |
Business activity
The main business activities of Dfe Pharma India are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Dfe Pharma India Private Limited, buy the company report.
Financials of Dfe Pharma India Private Limited
FY 2024 filings availableDfe Pharma India Private Limited reported revenue of ₹571.98 Cr (up 26% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 29% over five years, including 26% growth in the latest year. EBITDA fell 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹30.29 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹13.91 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.3% | ||||
| Net Profit Margin | 2.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dfe Pharma India Private Limited, buy the company report.
Board of directors of Dfe Pharma India Private Limited
Dfe Pharma India has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jaya Prabbu Subbaraj | Director | 01 Nov 2019 | 6 Years 11 Months | Current |
| Aditya Chitharanjan Also directs: Chith Warehouse Private Limited | Director | 01 Jan 2021 | 5 Years 9 Months | Current |
| Preetam Talanki Nagaraja Shetty | Director | 01 Apr 2022 | 4 Years 6 Months | Current |
| Sven Jorg Willi Max Abend | Director | 21 May 2025 | 1 Years 5 Months | Current |
Peer comparison
Dfe Pharma India Private Limited is compared with the 5 companies closest to it by revenue in the Business Services industry (Business Auxiliary Services, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| H.B. Fuller India Adhesives Private Limited | ₹575.65 Cr (FY 2025) | 14.0% | Shirwal, Maharashtra, India | |||
| Dfe Pharma India Private Limitedthis company | ₹571.98 Cr (FY 2025) | ₹13.91 Cr | 2.4% | 26.0% | 134 | Cuddalore, Tamil Nadu, India |
| Finorchem Limited | ₹558.51 Cr (FY 2025) | 3.0% | Kolkata, West Bengal, India | |||
| Fineotex Chemical Limited | ₹557.64 Cr (FY 2025) | -5.0% | Mumbai, Maharashtra, India | |||
| Benzo Chem Industries Pvt Ltd | ₹554.12 Cr (FY 2025) | 13.0% | Mumbai, Maharashtra, India | |||
| Ganga Rasayanie Pvt Ltd | ₹550.14 Cr (FY 2024) | 2.0% | Kolkata, West Bengal, India |
To see the full peer comparison of Dfe Pharma India Private Limited, buy the company report.
Auditor
Dfe Pharma India Private Limited is audited by Choksey Bhargava & Co LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Choksey Bhargava & Co LLP | FY 2023 | 000059N/N500010 |
Shareholding
The shareholding of Dfe Pharma India Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Dfe Pharma India Private Limited, buy the company report.
Deals & funding
Dfe Pharma India Private Limited has 2 deals on record (2 secondary share transfers); the latest was in March 2022.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: Dfe Pharma B.v., Dfe Pharma (Sea Pte Ltd Seller: DFE Pharma Excipients B.V., DFE Pharma Excipients (Sea) Pte. Ltd. |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: DFE Pharma Excipients (Sea) Pte. Ltd., DFE Pharma Excipients B.V. Seller: Dfe Pharma (Sea Pte Ltd, an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Dfe Pharma India Private Limited has 6 court cases on record: 6 filed by Dfe Pharma India. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 0 | 0 |
Cases on record (5 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Madras High Court | Court case (CRL OP) | Filed by the company against The State Rep.By, the Inspector of Police, | Disposed |
| Madras High Court | Court case (CRL MP) | Filed by the company against The State Rep.By, the Inspector of Police, | Disposed |
| Madras High Court | Writ petition | Filed by the company against The Additional Commissioner of CGST and Central Excise | Disposed |
| Madras High Court | Court case (WMP(MD)) | Filed by the company against The Additional Commissioner of CGST and Central Excise | Disposed |
| Madras High Court | Court case (WP Crl.) | Filed by the company against an individual | Disposed |
To see the full case history of Dfe Pharma India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Dfe Pharma India Private Limited has 12 MSME Form 1 returns on record between 2020 and 2024, listing 1,071 overdue payments to 53 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 53)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Be Well Hospitals Private Limited | |||
| an individual supplier | |||
| Hosokawa Micron India Private Limited | |||
| Tasira Instruments and Services | |||
| Classic Roadways Private Limited |
To see the full MSME payment records of Dfe Pharma India Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Dfe Pharma India Private Limited has a workforce of 134 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
GST
Dfe Pharma India has 4 GST registrations: 4 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAHCD2694R1Z0 | Tamil Nadu | Active | 26 Jun 2019 |
| 27AAHCD2694R1ZT | Maharashtra | Active | 04 Jul 2019 |
| 29AAHCD2694R1ZP | Karnataka | Active | 04 Jul 2019 |
| 36AAHCD2694R1ZU | Telangana | Active | 16 Nov 2021 |
To see the full GST registrations and return filing status of Dfe Pharma India Private Limited, buy the company report.
Recent activity
Dfe Pharma India Private Limited has 12 board changes on record since 2019: 8 appointments and 4 cessations. The latest: Sven Jorg Willi Max Abend was appointed as Director on 21 May 2025.
3 earlier events are in the company report.
News
Frequently asked questions
Dfe Pharma India is an active foreign private limited company based in Cuddalore, Tamil Nadu, India. The company works in business support services, within the business services industry. It was incorporated on 15 May 2019 (7+ years old) and is registered under CIN U24299TN2019FTC129309.
Dfe Pharma India has 4 current directors:
- Jaya Prabbu Subbaraj - Director
- Aditya Chitharanjan - Director
- Preetam Talanki Nagaraja Shetty - Director
- Sven Jorg Willi Max Abend - Director
The latest financial statements of Dfe Pharma India on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 18 September 2024. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Dfe Pharma India is 33AAHCD2694R1Z0, registered in Tamil Nadu. The company has 4 GST registrations in all, of which 4 are active. Other active GSTINs include 27AAHCD2694R1ZT (Maharashtra), 29AAHCD2694R1ZP (Karnataka), 36AAHCD2694R1ZU (Telangana).
The CIN (Corporate Identification Number) of Dfe Pharma India is U24299TN2019FTC129309. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dfe Pharma India has 6 court cases on record: 6 filed by the company.
Dfe Pharma India was incorporated on 15 May 2019, making it 7+ years old. It is registered with the Registrar of Companies, Chennai.
Dfe Pharma India has 2 deals on record (2 secondary share transfers); the latest was in March 2022.
The peers of Dfe Pharma India by revenue are H.B. Fuller India Adhesives Private Limited, Finorchem Limited, Fineotex Chemical Limited, Benzo Chem Industries Pvt Ltd, Ganga Rasayanie Pvt Ltd, all in the Business Services industry (Business Auxiliary Services, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sven Jorg Willi Max Abend was appointed as Director on 21 May 2025. Martti Tapani Ossian Hedman ceased to be Director on 01 Feb 2025. Martti Tapani Ossian Hedman was appointed as Director on 26 Apr 2022. Dfe Pharma India has 12 board changes on record in total.
Dfe Pharma India has 12 MSME Form 1 returns on record between 2020 and 2024, listing 1,071 overdue payments to 53 micro and small suppliers. The latest return was filed on 01 May 2024.
Dfe Pharma India can be reached through the website dfepharma.com. Its registered office is in Cuddalore, Tamil Nadu, India.